Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. (ARQT): 16 pipeline candidates · ~8 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
8.0 months
D/E 1.43 · 0% dilution
Lead: Phase 3
16 candidates
N/A
0 buys · 37 sells (180d)
A transparent, data-derived signal for Arcutis Biotherapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$3.0B
Cash
$35.1M
Quarterly Burn
$104.7M
Runway
8.0 mo
Revenue
$105.4M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (16 candidates)
| Drug | Phase |
|---|---|
| ARQ-151 cream 0.05% | Phase 2 |
| ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05% | Phase 3 |
| ARQ-154 Foam 0.3% | Phase 1 |
| ARQ-234 | Phase 1 |
| ARQ-252 | Phase 1 |
| ARQ-255 | Phase 1 |
| Roflumilast Cream 0.05% | Phase 3 |
| Roflumilast Foam 0.3% | Phase 3 |
| Vehicle Cream | Phase 3 |
| Vehicle Foam | Phase 3 |
Showing 10 of 16 candidates. Sign up for full pipeline.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
266
Total value held
$2.83B
| Holder | Shares | Value |
|---|---|---|
| suvretta capital management, llc | 12,327,000 | $290.4M |
| vanguard capital management llc | 9,743,072 | $229.5M |
| blackrock, inc. | 9,200,411 | $216.8M |
| state street corp | 6,296,197 | $148.3M |
| polar capital holdings plc | 5,666,940 | $133.5M |
| jennison associates llc | 4,980,770 | $117.3M |
| gilder gagnon howe & co llc | 4,304,010 | $101.4M |
| morgan stanley | 4,218,931 | $99.4M |
| janus henderson group plc | 3,709,132 | $87.4M |
| ubs group ag | 3,329,224 | $78.4M |
Showing top 10 of 266 institutional holders of Arcutis Biotherapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Arcutis Biotherapeutics, Inc.'s pipeline?
Arcutis Biotherapeutics, Inc. (ARQT) has 16 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Arcutis Biotherapeutics, Inc.'s lead drug candidate?
Arcutis Biotherapeutics, Inc.'s most advanced tracked candidate is ARQ-151 cream 0.05% (Phase 2) for Atopic Dermatitis (Eczema).
What is Arcutis Biotherapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Arcutis Biotherapeutics, Inc. has approximately 8.0 months of cash runway.
What is Arcutis Biotherapeutics, Inc.'s market capitalization?
Arcutis Biotherapeutics, Inc.'s market capitalization is approximately $3.0B.
Who is the CEO of Arcutis Biotherapeutics, Inc.?
Mr. Todd Franklin Watanabe M.A. is the chief executive officer of Arcutis Biotherapeutics, Inc. (ARQT).
Get the full picture on Arcutis Biotherapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.